Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

Next Previous
Trial Profile

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms EXTEND
  • Sponsors Biogen

Most Recent Events

  • 28 Oct 2022 Results (of studies ADVANCE, ASCEND, DECIDE and EXTEND) assessing Machine learning parcellation of multiple sclerosis lesions into texturally consistent super-voxels for lesion classification presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 01 Oct 2022 This trial has been completed in Poland (End Date: 24 Sep 2018) according to European Clinical Trials Database record.
  • 31 Jul 2021 According to European Clinical Trials Database record, this study has been completed in Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top